About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT01210495

Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma

The study is designed to demonstrate that axitinib plus best supportive care is superior to placebo plus best supportive care in prolonging survival in patients with advanced hepatocellular carcinoma.

Lead sponsor: Pfizer•13 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Pfizer

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Locally advanced or metastatic HCC
•Failure of one prior antiangiogenic therapy including sorafenib, bevacizumab and brivanib.
•Child-Pugh Class A or B (score 7 only) disease.

Exclusion Criteria

•Prior treatment of advanced HCC with more than one prior first-line systemic therapy.
•Any prior local therapy within 2 weeks of starting the study treatment.
•Presence of hepatic encephalopathy and/or clinically relevant ascites.
•Presence of main portal vein invasion by HCC.

Related studies

RECRUITINGPhase 2

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

NCT06902246 · Unresectable Hepatocellular Carcinoma, Hepatocellular Carcinoma

RECRUITINGPhase 2

Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular Carcinoma

NCT07175441 · Advanced Unresectable Hepatocellular Carcinoma

RECRUITINGPhase 2

A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCC

NCT07422753 · Hepatocellular Carcinoma (HCC)

RECRUITINGPhase 2

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

NCT05969860 · Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, and more

RECRUITINGPhase 1

A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

NCT06427941 · Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 9, 2019Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment224

Start dateDec 2010

Last updatedJan 9, 2019

Condition

Hepatocellular Carcinoma

Locations shown

Alta Bates Summit Comprehensive Cancer Center

Berkeley, California

UCSD Medical Center- La Jolla

La Jolla, California

Moores UCSD Cancer Center

La Jolla, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 9, 2019Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions